Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02632409 · ClinicalTrials.gov registry record · Phase 3
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
A Phase 3 study of Various Advanced Cancer, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 3
- Development phase
- 709
- Enrollment target
- 20
- Study locations
NCT02632409 is a Phase 3 study of Various Advanced Cancer that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 709 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT02632409, a Phase 3 study of Various Advanced Cancer, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 709 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Nivolumab
Study Locations (20)
California
- Local Institution - 0061 - Clovis
- Local Institution - 0172 - Sacramento
- Local Institution - 0005 - San Francisco
Florida
- Local Institution - 0167 - Gainesville
- Local Institution - 0030 - Miami Beach
- Local Institution - 0008 - Tampa
New York
- Local Institution - 0176 - Albany
- Local Institution - 0157 - Buffalo
- Local Institution - 0007 - Mineola
Minnesota
- Local Institution - 0051 - Burnsville
- Local Institution - 0004 - Rochester
Alaska
- Alaska Urological Institute dba Alaska Clinical Research Center - Anchorage
Arizona
- Local Institution - 0179 - Tucson
Colorado
- Local Institution - 0178 - Lakewood
Illinois
- Local Institution - 0168 - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 709 participants |
| Start Date | 2016-03-22 |
| Est. Completion | 2027-05-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02632409
The ClinicalTrials.gov registry entry for NCT02632409 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 709 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Various Advanced Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02632409 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT02632409 about?
NCT02632409 is a clinical study titled "An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer". The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.
What is the current status of trial NCT02632409?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 709 participants. The study started on 2016-03-22. Estimated completion is 2027-05-27.
What conditions does trial NCT02632409 study?
This clinical trial studies the following conditions: Various Advanced Cancer.
What interventions are being tested in trial NCT02632409?
The interventions under investigation include: Placebo (OTHER), Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02632409?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02632409 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.